In silico analyses identify gene-sets, associated with clinical outcome in ovarian cancer: role of mitotic kinases
Metrics: PDF 1524 views | HTML 2237 views | ?
Alberto Ocaña1, Javier Pérez-Peña1, Ana Alcaraz-Sanabria1, Verónica Sánchez-Corrales1, Cristina Nieto-Jiménez1, Arnoud J. Templeton2, Bostjan Seruga3, Atanasio Pandiella4, Eitan Amir5
1Translational Research Unit, Albacete University Hospital, Albacete, Spain
2Department of Medical Oncology and Hematology, St Gallen, Switzerland
3Department of Medical Oncology, Institute of Oncology Ljubljana, Ljubljana, Slovenia
4Cancer Research Center, CSIC-University of Salamanca, Spain
5Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University of Toronto, Toronto, Canada
Alberto Ocaña, e-mail: [email protected]
Keywords: mitotic kinases, AURKB, protein kinases, ovarian cancer, cell cycle
Received: November 27, 2015 Accepted: February 23, 2016 Published: March 16, 2016
Introduction: Accurate assessment of prognosis in early stage ovarian cancer is challenging resulting in suboptimal selection of patients for adjuvant therapy. The identification of predictive markers for cytotoxic chemotherapy is therefore highly desirable. Protein kinases are important components in oncogenic transformation and those relating to cell cycle and mitosis control may allow for identification of high-risk early stage ovarian tumors.
Methods: Genes with differential expression in ovarian surface epithelia (OSE) and ovarian cancer epithelial cells (CEPIs) were identified from public datasets and analyzed with dChip software. Progression-free (PFS) and overall survival (OS) associated with these genes in stage I/II and late stage ovarian cancer was explored using the Kaplan Meier Plotter online tool.
Results: Of 2925 transcripts associated with modified expression in CEPIs compared to OSE, 66 genes coded for upregulated protein kinases. Expression of 9 of these genes (CDC28, CHK1, NIMA, Aurora kinase A, Aurora kinase B, BUB1, BUB1βB, CDKN2A and TTK) was associated with worse PFS (HR:3.40, log rank p<0.001). The combined analyses of CHK1, CDKN2A, AURKA, AURKB, TTK and NEK2 showed the highest magnitude of association with PFS (HR:4.62, log rank p<0.001). Expression of AURKB predicted detrimental OS in stage I/II ovarian cancer better than all other combinations
Conclusion: Genes linked to cell cycle control are associated with worse outcome in early stage ovarian cancer. Incorporation of these biomarkers in clinical studies may help in the identification of patients at high risk of relapse for whom optimizing adjuvant therapeutic strategies is needed.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.